Attend the FierceBiotech 3rd Drug Development Forum!
The leading executive-level forum for biotech strategy & networking | Oct 1-3 | Boston
Quest Diagnostics, the New Jersey-based diagnostics maker, will close its Troy, Michigan, laboratory by early May, laying off 57 workers at the facility.…
The series B round will fund a device Vectorious sees improving outcomes and cutting costs in an indication dogged by stubbornly high mortality rates.
Helix plans to expand its DNA test marketplace this year to offer over 50 products, including launches from companies like Mayo Clinic.
The genetic diagnostics business will use the cash to increase access to its tests outside of India’s biggest cities.
The startup sees the test enabling the detection of cancers and stratification of patients through the analysis of exhaled volatile organic compounds.
The round equips Gelesis to get its manufacturing and commercial arms ready for launch should regulators look favorably on its mixed late-phase data.
Grail, which seeks to develop liquid biopsies to catch cancer early, is looking at an initial public offering in Hong Kong, Bloomberg reported.
The plan is to use the IPO money to introduce a string of new products over the next few years.
Cota, a healthcare data analytics company, will use the funds to advance its Cota Nodal Address disease classification system.
NnBU is developing a blockchain-based device that exposes babies born via c-section to conditions comparable to those in the birth canal.